Navigation Links
Pfizer to Acquire FoldRx Pharmaceuticals
Date:9/1/2010

NEW YORK and CAMBRIDGE, Mass., Sept. 1 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) and FoldRx Pharmaceuticals, Inc., a privately held drug discovery and clinical development company, today announced that they have entered into an agreement under which Pfizer will acquire FoldRx.  

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

(Logo: http://photos.prnewswire.com/prnh/20100901/NY58014LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100901/NY58014LOGO)

FoldRx's portfolio includes clinical and pre-clinical programs for investigational compounds to treat diseases caused by protein misfolding, which is increasingly recognized as an underlying cause in many chronic degenerative diseases.  The company's lead product candidate, tafamidis meglumine, is in registration as an oral, disease-modifying therapy for TTR amyloid polyneuropathy (ATTR-PN), a progressively fatal genetic neurodegenerative disease, for which liver transplant is the only treatment option that is currently available.  

FoldRx has filed a marketing authorization application (MAA) for tafamidis with the European Medicines Agency, and is currently in communication with the FDA to define its pathway for filing in the U.S.  Tafamidis has orphan drug designation in both the U.S. and European Union (EU) and Fast Track designation in the U.S. for the treatment of ATTR-PN.  

"By combining FoldRx's proprietary expertise in identifying and developing treatments for protein misfolding diseases with Pfizer's commercial, medical and regulatory expertise, and global strengths in patient services and reimbursement, we are taking a significant step toward potentially bringing, for the first time, a non-surgical treatment option for underserved patients affected by the deadly disease
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. , Sept. 30, 2014  Hologic, Inc. ... Stephen MacMillan , Hologic,s President and Chief Executive Officer, ... Ceremony on October 1, the first day of Breast ... discuss the Company,s campaign focused on the important benefits ... approved by the FDA as clinically superior to traditional ...
(Date:9/30/2014)... , Sept. 30, 2014 This ... for molecular imaging informatics solutions including nuclear imaging ... and comparison. The study assesses the size of ... 2010 and 2013, and projects future growth based ... as the dynamics taking place in the broader ...
(Date:9/30/2014)... , Sept. 30, 2014 Aileron Therapeutics, ... Summary Global Markets Direct,s, ,Aileron Therapeutics, Inc. ... overview of the Aileron Therapeutics, Inc.,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... various stages, therapeutics assessment by drug target, mechanism ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3
... nationally recognized, certified practice management and electronic ... its annual Customer Conference at the Magic City,s renowned ... A record 361 attendees registered for this ... last year,s figures. "Spotlight on Success" was chosen as ...
... RIDGEFIELD, Conn., May 19, 2011 Boehringer Ingelheim ... (dabigatran etexilate mesylate) capsules has received preferred ... Part D plans through its pharmacy benefits manager, ... include AARP Medicare Rx and AARP MedicareComplete from ...
Cached Medicine Technology:SuccessEHS "Spotlight on Success" Customer Conference Begins 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 2Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 3Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 4Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 5Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage 6
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
(Date:10/1/2014)... 2014 NoteSwift Inc., announced today their ... 12.1 and 13.0. NoteSwift is the bridge between the ... navigate and document clinical information at the point of ... a patient note by more than half – and ... pain points providers state impedes EHR use according to ...
(Date:10/1/2014)... 2014 On Sept. 9, Chapín Coffee ... the Martha Stewart American Made Awards (MSAMAs), an annual ... country in the fields of crafts, design, food and ... a finalist in the MSAMAs, which celebrates entrepreneurs and ... improving local communities and changing the way we shop, ...
(Date:10/1/2014)... October is national Breast Cancer Awareness Month—an ... while raising money for breast cancer research. Pelican Water ... in the effort to find a cure. ... of having access to clean, healthy water. Research has ... certain forms of cancer. , The Problem of ...
(Date:10/1/2014)... OXNARD, CA (PRWEB) October 01, 2014 ... of the Anacapa Dental Art Institute in Oxnard and ... of Bangalore providing full mouth rehabilitation training. , “Speaking ... need of these transformative procedures to get the help ... mouth rehabilitation may involve repairing previous dental work, providing ...
Breaking Medicine News(10 mins):Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2Health News:Pelican Water Supports Breast Cancer Awareness Month with Order Donations 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 2Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 3Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 4Health News:Internationally Respected Oxnard Dentist Concludes All-on-4™ Dental Implants Training Today 5
... syndrome) has been a major killer in the last two ... worldwide and infected a further 8,000. A collaborative group of ... past year screening more than 8,000 existing drugs to find ... 15 existing drugs that have the potential to kill the ...
... the womb of the mother, may have asthma at a ... an 11-year observation of incidence of asthma and other respiratory ... to incidence of asthma in childhood. Passive smoking by the ... of asthma in children. ,Researchers are of the opinion ...
... Parkinson's disease is a neurodegenerative disease of the substantia nigra ... first discovered and its symptoms documented in 1817 by the ... in the brain of patients were identified in the 1960s. ... a mystery. , ,In a study done recently it ...
... have found sections of the // chromosomes of lung ... ,In a study in the July 1 issue ... nucleotide polymorphism (SNP) array technology, which focuses on the ... chromosomes where genes were either left out or multiplied ...
... autistic children have led to a fear in the world ... epidemic. However a recent report, which was published in the ... is not true. The report points out to certain facts ... ,The study had pointed out that recent changes in the ...
... that walking on a cobblestone mat surface resulted in ... physical performance among the age groups of 60 and ... said that Compared to conventional walking, the experience ... manufactured cobblestone mats improved participants' balance, measures of mobility, ...
Cached Medicine News:Health News:Re –growing Brain cells destroyed by Parkinson’s disease 2Health News:Possible location of lung cancer genes found 2Health News:Cobblestone Walking May Be The Key For Healthy Living. 2